rovalpituzumab in small cell lung cancer (sclc)
Published 7 years ago • 232 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
7:14
safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (sclc)
-
2:13
trinity: rova-t for relapsed sclc
-
1:31
dr. bauer on rovalpituzumab tesirine in patients with sclc
-
1:18
checkpoint inhibitors in small cell lung cancer (sclc)
-
1:51
dr. bauer on rovalpituzumab tesirine in sclc
-
0:58
no clear evidence for benefit with addition of rova-t to chemo for extensive sclc
-
1:02
evaluating the role of systemic therapies in sclc
-
2:47
update from a phase 1 study of amg 757 in sclc
-
2:24
the dll3-targeting bite, tarlatamab, for the treatment of sclc
-
1:52
phase i trial of bi 764532, a t-cell engager for dll3-positive nec and sclc
-
4:43
first in-human trials of rovalpituzumab for sclc
-
1:13
guiding nsclc treatment with biomarkers
-
5:34
new data in sclc including the convert and rovalpituzumab
-
3:28
bispecific antibodies in lung cancer
-
1:15
dll3, a new biomarker for neuroendocrine tumors of the lung
-
6:04
arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
-
1:41
iasc wclc 2021: cx-2029 and amg 757 for lung cancer
-
7:53
case 3: chemoimmunotherapy in sclc
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients